Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin for Prevention of Post-ERCP Pancreatitis in Patients With Prior Biliary Sphincterotomy
NCT07661498Phase 4Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jul 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Incidence of Post-ERCP Pancreatitis at 30 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT07661498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661498.